Articles

UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10307) 10307
Newsletter (23) 23
Book Chapter (21) 21
Magazine Article (21) 21
Newspaper Article (19) 19
Book / eBook (5) 5
Publication (3) 3
Government Document (2) 2
Web Resource (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (6243) 6243
science & technology (5767) 5767
life sciences & biomedicine (5530) 5530
animals (5265) 5265
female (5265) 5265
skin neoplasms - chemically induced (4957) 4957
mice (4192) 4192
male (3883) 3883
biological and medical sciences (3010) 3010
medical sciences (2855) 2855
middle aged (2322) 2322
oncology (2224) 2224
skin neoplasms - pathology (2052) 2052
dermatology (2051) 2051
tumors (1914) 1914
aged (1733) 1733
adult (1594) 1594
skin neoplasms - drug therapy (1333) 1333
carcinogens (1067) 1067
cancer (1057) 1057
papilloma - chemically induced (1038) 1038
skin (1022) 1022
neoplasms, experimental - chemically induced (983) 983
antineoplastic agents - adverse effects (904) 904
skin cancer (898) 898
skin - drug effects (888) 888
skin - pathology (823) 823
skin neoplasms - prevention & control (813) 813
melanoma (802) 802
skin neoplasms - genetics (793) 793
9,10-dimethyl-1,2-benzanthracene (785) 785
carcinoma, squamous cell - chemically induced (784) 784
pharmacology. drug treatments (759) 759
time factors (751) 751
melanoma - drug therapy (736) 736
carcinogenesis, carcinogens and anticarcinogens (734) 734
rats (686) 686
skin neoplasms - metabolism (685) 685
abridged index medicus (654) 654
carcinogens - toxicity (603) 603
chemical agents (602) 602
risk factors (582) 582
dose-response relationship, drug (580) 580
skin diseases - chemically induced (559) 559
care and treatment (558) 558
treatment outcome (527) 527
tetradecanoylphorbol acetate (523) 523
research (515) 515
antineoplastic agents - therapeutic use (507) 507
toxicology (506) 506
aged, 80 and over (491) 491
biochemistry & molecular biology (472) 472
skin and connective tissue diseases (462) 462
antineoplastic agents (461) 461
cell biology (460) 460
carcinogenesis (459) 459
skin neoplasms - etiology (456) 456
skin - metabolism (445) 445
tumors of the skin and soft tissue. premalignant lesions (445) 445
research article (436) 436
mice, inbred strains (435) 435
carcinoma, squamous cell - pathology (431) 431
chemotherapy (425) 425
pharmacology & pharmacy (417) 417
9,10-dimethyl-1,2-benzanthracene - toxicity (400) 400
tetradecanoylphorbol acetate - toxicity (396) 396
neoplasms - chemically induced (390) 390
mutation (389) 389
melanoma - pathology (376) 376
cocarcinogenesis (372) 372
mice, inbred c57bl (372) 372
breast cancer (368) 368
squamous cell carcinoma (365) 365
apoptosis (357) 357
administration, topical (356) 356
health aspects (353) 353
breast neoplasms - drug therapy (348) 348
papilloma - pathology (347) 347
analysis (345) 345
disease models, animal (337) 337
mice, transgenic (337) 337
drug eruptions - etiology (335) 335
metastasis (327) 327
rodents (321) 321
antineoplastic combined chemotherapy protocols - adverse effects (311) 311
neoplasms - drug therapy (309) 309
cell line, tumor (305) 305
lung neoplasms - chemically induced (303) 303
melanoma - chemically induced (297) 297
antibodies, monoclonal - adverse effects (291) 291
gene expression (290) 290
adolescent (287) 287
drug toxicity and drugs side effects treatment (277) 277
follow-up studies (277) 277
skin neoplasms - immunology (276) 276
immunohistochemistry (274) 274
skin neoplasms - epidemiology (274) 274
cells, cultured (263) 263
proteins (263) 263
retrospective studies (262) 262
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (9707) 9707
German (262) 262
French (164) 164
Russian (144) 144
Japanese (138) 138
Spanish (48) 48
Italian (25) 25
Polish (23) 23
Chinese (19) 19
Danish (17) 17
Dutch (10) 10
Portuguese (9) 9
Hungarian (5) 5
Czech (4) 4
Norwegian (3) 3
Swedish (3) 3
Hebrew (2) 2
Bulgarian (1) 1
Croatian (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Inhibition of CXCR2 profoundly suppresses inflammation-driven and spontaneous tumorigenesis
by Jamieson, Thomas and Clarke, Mairi and Steele, Colin W and Samuel, Michael S and Neumann, Jens and Jung, Andreas and Huels, David and Olson, Michael F and Das, Sudipto and Nibbs, Robert J. B and Sansom, Owen J
The Journal of clinical investigation, ISSN 0021-9738, 09/2012, Volume 122, Issue 9, pp. 3127 - 3144
Life Sciences & Biomedicine | Medicine, Research & Experimental | Science & Technology | Research & Experimental Medicine | Dextran Sulfate | Tetradecanoylphorbol Acetate | Adenocarcinoma - pathology | Colitis - pathology | Colonic Neoplasms - chemically induced | Mice, 129 Strain | Receptors, Interleukin-8B - antagonists & inhibitors | Receptors, Interleukin-8B - deficiency | Colonic Neoplasms - metabolism | Adenoma - metabolism | Adenocarcinoma - metabolism | Azoxymethane | Colitis - chemically induced | Statistics, Nonparametric | Papilloma - pathology | Precancerous Conditions - pathology | Neutrophils - metabolism | Papilloma - chemically induced | Papilloma - metabolism | Skin Neoplasms - pathology | Dermatitis, Contact - pathology | Gene Expression | Neutrophils - enzymology | Mice, Inbred C57BL | Skin Neoplasms - chemically induced | Tumor Burden | Chemokines, CXC - genetics | Chemokines, CXC - secretion | Mice, Knockout | Skin Neoplasms - metabolism | Animals | Cell Transformation, Neoplastic | Adenoma - secretion | Chemokines, CXC - metabolism | Receptors, Interleukin-8B - genetics | Animals, Inbred Strains | 9,10-Dimethyl-1,2-benzanthracene | Mice | Mice, Inbred BALB C | Precancerous Conditions - chemically induced | Colonic Neoplasms - secretion | Adenoma - chemically induced | Peroxidase - metabolism | Care and treatment | Cancer cells | Neutrophils | Papilloma | Genetic aspects | Diagnosis | Adenoma | Research | Gene expression | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Chemically induced skin carcinogenesis: Updates in experimental models (Review)
by Neagu, Monica and Caruntu, Constantin and Constantin, Carolina and Boda, Daniel and Zurac, Sabina and Spandidos, Demetrios A and Tsatsakis, Aristidis M
Oncology reports, ISSN 1021-335X, 05/2016, Volume 35, Issue 5, pp. 2516 - 2528
Chemically induced carcinogenesis | Mouse model | Skin cancer | Life Sciences & Biomedicine | Oncology | Science & Technology | Carcinogenesis - drug effects | Animals | Skin Neoplasms - drug therapy | Skin Neoplasms - immunology | Carcinogenesis - immunology | Humans | Skin Neoplasms - chemically induced | Skin - pathology | Disease Models, Animal | Drug Screening Assays, Antitumor | Index Medicus
Journal Article
Details down arrow
3. Full Text Safety and Efficacy of Immune Checkpoint Inhibitors in Patients on Dialysis: A Retrospective Case Series
by Strohbehn, Ian A and Lee, Meghan and Seethapathy, Harish and Chute, Donald and Rahma, Osama and Guidon, Amanda and Neilan, Tomas G and Zlotoff, Daniel A and Okin, Daniel and Rengarajan, Michelle and Reynolds, Kerry and Sise, Meghan E
American journal of kidney diseases, ISSN 0272-6386, 08/2020, Volume 76, Issue 2, pp. 299 - 302
Hypothyroidism - chemically induced | Lung Neoplasms - drug therapy | Melanoma - complications | Myocarditis - chemically induced | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Myositis - chemically induced | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Carcinoma, Merkel Cell - drug therapy | Neoplasms - complications | Pneumonia - chemically induced | Carcinoma, Merkel Cell - complications | Aged, 80 and over | Female | Urogenital Neoplasms - complications | Urogenital Neoplasms - drug therapy | Retrospective Studies | Adrenal Gland Diseases - chemically induced | Head and Neck Neoplasms - drug therapy | Treatment Outcome | Lung Neoplasms - complications | Neoplasms - drug therapy | Kidney Failure, Chronic - therapy | Skin Neoplasms - complications | B7-H1 Antigen - antagonists & inhibitors | Antineoplastic Agents, Immunological - therapeutic use | Melanoma - drug therapy | Kidney Failure, Chronic - complications | Head and Neck Neoplasms - complications | Aged | CTLA-4 Antigen - antagonists & inhibitors | Renal Dialysis | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
by Jeffrey S. Weber and Katharina C. Kähler and Axel Hauschild
Journal of clinical oncology, ISSN 0732-183X, 07/2012, Volume 30, Issue 21, pp. 2691 - 2697
Life Sciences & Biomedicine | Oncology | Science & Technology | Biological and medical sciences | Medical sciences | Tumors | Stevens-Johnson Syndrome - immunology | Peripheral Nervous System Diseases - chemically induced | Skin Neoplasms - drug therapy | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Scleritis - chemically induced | Antineoplastic Agents - administration & dosage | Liver - immunology | Liver - drug effects | Antineoplastic Agents - adverse effects | Diarrhea - immunology | Pancreatitis - immunology | Scleritis - immunology | Mucous Membrane - drug effects | Colitis - immunology | Peripheral Nervous System Diseases - immunology | Antibodies, Monoclonal - immunology | Drug Eruptions - immunology | Skin - immunology | Melanoma - metabolism | Skin Neoplasms - pathology | Skin Neoplasms - immunology | Antineoplastic Agents - immunology | CTLA-4 Antigen - drug effects | Lymphatic Diseases - immunology | Antibodies, Monoclonal - pharmacokinetics | CTLA-4 Antigen - immunology | Pancreatitis - chemically induced | Melanoma - secondary | Chemical and Drug Induced Liver Injury - immunology | Pituitary Gland - immunology | Skin Neoplasms - metabolism | Lymphatic Diseases - chemically induced | Mucous Membrane - immunology | Antibodies, Monoclonal - administration & dosage | Melanoma - immunology | Uveitis - immunology | Melanoma - drug therapy | Uveitis - chemically induced | Pituitary Gland - drug effects | Skin - drug effects | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Talimogene laherparepvec improves durable response rate in patients with advanced melanoma
by Andtbacka, Robert H.I and Kaufman, Howard L and Collichio, Frances and Amatruda, Thomas and Senzer, Neil and Chesney, Jason and Delman, Keith A and Spitler, Lynn E and Puzanov, Igor and Agarwala, Sanjiv S and Milhem, Mohammed and Cranmer, Lee and Curti, Brendan and Lewis, Karl and Ross, Merrick and Guthrie, Troy and Linette, Gerald P and Daniels, Gregory A and Harrington, Kevin and Middleton, Mark R and Miller, Wilson H and Zager, Jonathan S and Ye, Yining and Yao, Bin and Li, Ai and Doleman, Susan and Van Der Walde, Ari and Gansert, Jennifer and Coffin, Robert S
Journal of clinical oncology, ISSN 0732-183X, 09/2015, Volume 33, Issue 25, pp. 2780 - 2788
Life Sciences & Biomedicine | Oncology | Science & Technology | United States - epidemiology | Immunotherapy - methods | Adjuvants, Immunologic - administration & dosage | Skin Neoplasms - drug therapy | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Adjuvants, Immunologic - adverse effects | Chills - chemically induced | Skin Neoplasms - prevention & control | Melanoma - prevention & control | Time Factors | Antineoplastic Agents - adverse effects | Injections, Intralesional | Skin Neoplasms - mortality | Aged, 80 and over | Adult | Female | Odds Ratio | Adjuvants, Immunologic - therapeutic use | Skin Neoplasms - pathology | Skin Neoplasms - immunology | Treatment Outcome | Granulocyte-Macrophage Colony-Stimulating Factor - drug effects | Melanoma - secondary | Oncolytic Virotherapy | Herpesvirus 1, Human | Granulocyte-Macrophage Colony-Stimulating Factor - immunology | Melanoma - immunology | Melanoma - drug therapy | Survival Analysis | Aged | Oncolytic Viruses | Neoplasm Staging | Melanoma - mortality | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial
by Falchook, Gerald S, Dr and Long, Georgina V, PhD and Kurzrock, Razelle, Prof and Kim, Kevin B, MD and Arkenau, Tobias H, PhD and Brown, Michael P, PhD and Hamid, Omid, MD and Infante, Jeffrey R, MD and Millward, Michael, MD and Pavlick, Anna C, MD and O’Day, Steven J, MD and Blackman, Samuel C, PhD and Curtis, C Martin, BA and Lebowitz, Peter, PhD and Ma, Bo, PhD and Ouellet, Daniele, PhD and Kefford, Richard F, Prof
The Lancet (British edition), ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1893 - 1901
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Tumors of the skin and soft tissue. Premalignant lesions | Neurology | General aspects | Tumors of the nervous system. Phacomatoses | Dermatology | Biological and medical sciences | Medical sciences | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic breast cancer
by Orlando, Laura and Cardillo, Anna and Ghisini, Raffaella and Rocca, Andrea and Balduzzi, Alessandra and Torrisi, Rosalba and Peruzzotti, Giulia and Goldhirsch, Aron and Pietri, Elisabetta and Colleoni, Marco
BMC cancer, ISSN 1471-2407, 09/2006, Volume 6, Issue 1, pp. 225 - 225
Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Cyclophosphamide - administration & dosage | Humans | Middle Aged | Neoplasm Proteins - immunology | Bone Neoplasms - secondary | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Cyclophosphamide - adverse effects | Bone Neoplasms - blood supply | Leukopenia - chemically induced | Receptor, ErbB-2 - antagonists & inhibitors | Receptor, ErbB-2 - immunology | Liver Neoplasms - secondary | Combined Modality Therapy | Lung Neoplasms - therapy | Lymphatic Metastasis | Breast Neoplasms - blood supply | Brain Neoplasms - drug therapy | Breast Neoplasms - drug therapy | Remission Induction | Methotrexate - adverse effects | Breast Neoplasms - genetics | Brain Neoplasms - therapy | Immunization, Passive | Methotrexate - administration & dosage | Trastuzumab | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Bone Neoplasms - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Brain Neoplasms - blood supply | Liver Neoplasms - therapy | Ventricular Dysfunction, Left - chemically induced | Breast Neoplasms - therapy | Antibodies, Monoclonal, Humanized | Brain Neoplasms - secondary | Lung Neoplasms - secondary | Angiogenesis Inhibitors - therapeutic use | Adult | Female | Bone Neoplasms - drug therapy | Neutropenia - chemically induced | Lung Neoplasms - blood supply | Drug Administration Schedule | Liver Neoplasms - drug therapy | Treatment Outcome | Gene Amplification | Liver Neoplasms - blood supply | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Genes, erbB-2 | Aged | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Management of toxicities of immune checkpoint inhibitors
by Spain, Lavinia and Diem, Stefan and Larkin, James
Cancer treatment reviews, ISSN 0305-7372, 2016, Volume 44, pp. 51 - 60
Hematology, Oncology and Palliative Medicine | Pembrolizumab | Immune-related adverse events | Renal cancer | Ipilimumab | Nivolumab | Lung cancer | Melanoma | Immune-checkpoint inhibitors | Life Sciences & Biomedicine | Oncology | Science & Technology | Lung Neoplasms - drug therapy | Skin Neoplasms - drug therapy | Humans | Immunosuppressive Agents - therapeutic use | Antibodies, Monoclonal - adverse effects | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Adrenal Cortex Hormones - therapeutic use | Diarrhea - chemically induced | Infliximab - therapeutic use | Drug Eruptions - drug therapy | Antineoplastic Agents - adverse effects | Colitis - chemically induced | Antilymphocyte Serum - therapeutic use | Colitis - drug therapy | Carcinoma, Renal Cell - drug therapy | Chemical and Drug Induced Liver Injury - etiology | Pituitary Diseases - chemically induced | Pituitary Diseases - drug therapy | Antibodies, Monoclonal, Humanized - adverse effects | Drug Eruptions - etiology | Neoplasms - drug therapy | Cyclosporine - therapeutic use | Tacrolimus - therapeutic use | Mycophenolic Acid - analogs & derivatives | Mycophenolic Acid - therapeutic use | Melanoma - drug therapy | Chemical and Drug Induced Liver Injury - drug therapy | Diarrhea - drug therapy | CTLA-4 Antigen - antagonists & inhibitors | Kidney Neoplasms - drug therapy | Thyroiditis - drug therapy | Thyroiditis - chemically induced | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Multicolour lineage tracing reveals clonal dynamics of squamous carcinoma evolution from initiation to metastasis
by Reeves, Melissa Q and Kandyba, Eve and Harris, Sophie and Del Rosario, Reyno and Balmain, Allan
Nature cell biology, ISSN 1465-7392, 06/2018, Volume 20, Issue 6, pp. 699 - 709
Life Sciences & Biomedicine | Science & Technology | Cell Biology | Tetradecanoylphorbol Acetate | Epithelial Cells - metabolism | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - metabolism | Carcinoma, Squamous Cell - chemically induced | Gene Expression Regulation, Neoplastic | Male | Cell Transformation, Neoplastic - chemically induced | Neoplasms, Experimental - chemically induced | Cell Movement - genetics | Neoplasms, Experimental - pathology | Time Factors | Cell Transformation, Neoplastic - genetics | Neoplasms, Experimental - genetics | Female | Tumor Burden - genetics | Skin Neoplasms - pathology | Cell Proliferation - genetics | Genetic Predisposition to Disease | Epithelial Cells - pathology | Mice, Transgenic | Skin Neoplasms - chemically induced | Cell Transformation, Neoplastic - metabolism | Skin Neoplasms - metabolism | Cell Lineage | Phenotype | Animals | Skin Neoplasms - genetics | 9,10-Dimethyl-1,2-benzanthracene | Carcinoma, Squamous Cell - secondary | Mutation | Neoplasms, Experimental - metabolism | Cell Transformation, Neoplastic - pathology | Genes, ras | Clonal Evolution | Squamous cell carcinoma | Cancer cells | Research | Epithelial cells | Benign | Evolution | Skin | Malignancy | Metastasis | Tumors | Skin cancer | Cancer | Metastases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights